Menu
Search
|

Menu

Close
X

Proteon Therapeutics Inc PRTO.OQ (NASDAQ Stock Exchange Global Market)

2.45 USD
+0.05 (+2.08%)
As of 1:30 AM IST
chart
Previous Close 2.40
Open 2.40
Volume 468
3m Avg Volume 5,259
Today’s High 2.45
Today’s Low 2.40
52 Week High 2.90
52 Week Low 1.27
Shares Outstanding (mil) 17.62
Market Capitalization (mil) 46.69
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.67 Mean rating from 6 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
-0.344
FY17
-2.116
FY16
-1.722
FY15
-1.298
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
--
5.73
Price to Book (MRQ)
vs sector
1.58
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
0.00
16.84
LT Debt to Equity (MRQ)
vs sector
0.00
12.51
Return on Investment (TTM)
vs sector
-65.10
14.61
Return on Equity (TTM)
vs sector
-65.10
16.34

EXECUTIVE LEADERSHIP

Paul Hastings
Chairman of the Board, Since 2016
Salary: --
Bonus: --
Timothy Noyes
President, CEO, Director, Since 2006
Salary: $487,190.00
Bonus: --
George Eldridge
Chief Financial Officer, Senior Vice President, Treasurer, Assistant Secretary, IR Contact Officer, Since 2013
Salary: $323,000.00
Bonus: --
E. Scott Toner
Senior Vice President - Marketing, Since 2015
Salary: --
Bonus: --
Steven Burke
Senior Vice President, Chief Medical Officer, Since 2006
Salary: $408,000.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

200 West St
WALTHAM   MA   02451-1121

Phone: +1781.8900102

Proteon Therapeutics, Inc. is a late-stage biopharmaceutical company, which focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular disease. The Company is involved in research and development activities. The Company's product candidate, product candidate, vonapanitase, formerly PRT-201, is a recombinant human elastase that it is developing to manage vascular access failure in patients with chronic kidney disease undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The Company has completed Phase II trial of vonapanitase in patients undergoing creation of an arteriovenous fistula (AVF). The Company initiated the first of two Phase III trials, PATENCY-1, for vonapanitase in radiocephalic AVFs. Its vonapanitase product candidate is a recombinant human elastase under development as a treatment to prevent AVF and arteriovenous graft (AVG) patency loss.

SPONSORED STORIES